An act relating to congenital cytomegalovirus
Vermont bill to address congenital cytomegalovirus through unspecified screening, prevention, or treatment measures for newborns and pregnant women.
Vermont bill to address congenital cytomegalovirus through unspecified screening, prevention, or treatment measures for newborns and pregnant women.
H 533 is a Vermont bill addressing congenital cytomegalovirus (CMV), a viral infection that can be transmitted from pregnant women to their fetuses, potentially causing hearing loss, developmental delays, and other serious complications in newborns. The bill's specific provisions are not detailed in the available information, but it likely relates to screening, prevention, treatment, or public health measures for this condition.
Congenital CMV is the most common congenital infection in the United States, affecting approximately 1 in 200 newborns, yet it remains largely undiagnosed without targeted screening. Early detection and intervention can significantly improve outcomes for affected children, including preventing or mitigating permanent hearing loss and developmental disabilities. This bill may establish protocols to identify and treat affected infants before irreversible damage occurs.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.